2 Quantum Computing Stocks That Could Make a Millionaire Quantum computing is still a high-risk frontier, but for patient investors, these two tickers could be tomorrow's generational wealth creators.
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
2 Financial Stocks Poised for a Comeback in 2026 Both stocks are in the Berkshire Hathaway portfolio, selected by former CEO Warren Buffett.
Supreme Court Nixed Trump Tariffs, But Will Companies Get Their Money Back? On Friday, the Supreme Court threw out President Donald Trump's signature emergency-law tariffs, but it did not spell out how the federal government should return the $133 billion already collected from importers.
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
My 5 Favorite Dividend Stocks to Buy Right Now There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Arohi Asset Exits a Big Software Bet by Selling 1.7M DoubleVerify (DV) Shares Worth $20.6 Million DoubleVerify provides digital media measurement and analytics tools for advertisers and publishers across multiple sectors.
Could Buying XRP Today Set You Up for Life? Turning a modest upfront investment in XRP into life-changing wealth is harder than it sounds.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Exclusive: Consumer Safety Expert Weighs In On Safety Rules, Affordability Debate In US Auto Sector As lawmakers question relevance of safety features amid affordability debate, this expert urged the need for regulations in the sector today.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio It's about striking that perfect balance between chasing growth and protecting what you already have.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Scaramucci: 'Yes, We're in a Bear Market,' So Get Bitcoin On Sunday, Anthony Scaramucci said he believes markets have slipped into a bear phase and argued the real issue is duration, not whether the downturn exists.
Vertiv Stock: Buy, Sell, or Hold? Vertiv has seen incredibly strong demand from data center operators for its cooling and power solutions.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
NVDA Earnings, Tariffs and Other Key Things to Watch this Week Markets enter a critical week dominated by Wednesday's Nvidia earnings and escalating geopolitical tensions as rising U.S.-Iran hostilities push oil prices higher.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Why Cleveland's Culture Scene Makes It a Retirement Pick That Doesn't Feel "Sleepy" Cleveland may sound like a sleepy little midwestern town. However, it's anything but sleepy.
Alphabet Has a Plan for Worldwide AI Dominance Will the tech giant be able to follow through on its aspirations?
This Fund Sold its Entire Stake in SSR Mining Stock After a 200% Rally. Should You Too? SSR Mining is a global precious metals producer with operations spanning gold, silver, and base metals across four continents.
Banking Crisis 2.0? The "Contagion" ETF That Gains 3% for Every 1% Banks Drop The Direxion Daily Financial Bear 3X Shares is still useful for some traders, but don't expect it to act like 2008 is back.
This 5% Dividend Stock Looks Safer Than You Think With high-occupancy and long-term lease terms, this REIT is built for stability. But, is it still a buy?
JPMorgan Acknowledges Shutting Down Trump Accounts After January 6 JPMorgan Chase & Co. (
NYSE: JPM ) acknowledged in a court filing that it shut down bank accounts tied to President Donald Trump and several of his businesses after the Jan. 6, 2021, Capitol riot, a point now sitting at the center of Trump's $5 billion lawsuit against the lender and its chief executive.
Iran's Khamenei Elevates Larijani as Prospects of War With US Grow Iran's supreme leader, Ayatollah Ali Khamenei, has elevated Ali Larijani into a de facto crisis manager role as Tehran braces for a possible clash with US and tries to keep the state functioning under pressure.
Men Vs. Women: Who Saves More — And Why It Matters Inflation data shows stubborn inflation, affecting savings and retirement readiness. Men have higher savings but women face structural realities.
Uber's CEO Just Delivered Disappointing News for Tesla Stock Investors It's time for investors to think about the progression of autonomous vehicle technology.
1 No-Brainer Artificial Intelligence (AI) Stock to Buy With $160 and Hold for the Long Term Palo Alto's business is going from strength to strength as it prepares customers for an increasingly dangerous cyber landscape.
